Jianpeng Zhang

Jianpeng Zhang

Auto-generated profile, based on publicly available information

Jianpeng Zhang

Department of Urology The First Affiliated Hospital of Guangzhou Medical University Guangzhou China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2025 in Cell Proliferation
Verified
Journal Article
Open access
YWYang Wu
Yang Wu
JZJianpeng Zhang
Jianpeng Zhang
WZWeixiong Zhu
Weixiong Zhu
XZXinrui Zhu
Xinrui Zhu
YLYi Liu
Yi Liu
SXShaohui Xu
Shaohui Xu
ARPC1B+ cancer stem cells (CSCs) in pancreatic cancer are identified as a subpopulation resistant to gemcitabine. In our study, drug repositioning, molecular docking, and surface plasmon resonance (SPR) technique jointly revealed that CK-636 can directly target ARPC1B protein with high affinity. In vitro cytotoxicity, ex vivo organoid cultures, in vivo xenograft and orthotopic gemcitabine-resistant pancreatic cancer model demonstrated that combination therapy of gemcitabine plus CK-636 showed a superior anti-tumor effect compared with gemcitabine monotherapy. Our study demonstrated that CK-636 can act as a rational adjuvant to overcome gemcitabine resistance in pancreatic cancer therapy.